






















Candida	 species	 are	 the	 most	 common	 cause	 of	 invasive	 fungal	 infections	 in	
immunocompromised	humans.	 Invasive	candidiasis	(IC)	has	an	associated	mortality	rate	of	
around	50%,	with	the	diploid,	pleomorphic	yeast,	Candida	albicans	responsible	for	up	to	60%	
of	 cases.	 Current	 immunodiagnostic	 tests	 for	 IC	 are	 based	 on	 the	 detection	 of	 circulating	
mannan	 antigen	 (Mn)	 and	 anti-mannan	 antibody	 (A-Mn)	 in	 a	 patient’s	 serum,	 using	 an	
enzyme-linked	immunosorbent	assay	(ELISA)	format.	The	high	rate	of	false	negative	results	in	
immunocompromised	 patients	 unable	 to	 produce	 sufficient	 levels	 of	 antibody,	 and	 false	
positive	 results	 in	 patients	with	 superficial,	 non-invasive	 colonisation	 has	 encouraged	 the	
development	of	new	non-invasive	immunodiagnostic	tests	that	rapidly	and	more	accurately	
detect	 IC.	 In	 this	 study,	hybridoma	technology	was	used	 to	produce	a	murine	monoclonal	
antibody	 (MAb),	MC3,	which	binds	 to	 a	 carbohydrate	 epitope	present	 on	 an	 extracellular	
mannan-containing	antigen	in	C.	albicans	yeast	and	hyphal	morphotypes.	The	MAb	is	highly	
specific,	reacting	with	antigens	from	several	Candida	species	known	to	cause	IC,	but	not	with	
antigens	 from	 a	 large	 number	 of	 clinically	 important	 fungi,	 including	 the	 invasive	 human	
pathogens	 Cryptococcus	 neoformans	 and	 Aspergillus	 fumigatus.	 The	 MAb	 was	 used	 in	
combination	 with	 a	 standard	 mycological	 growth	 medium	 to	 develop	 an	 ELISA	 for	
differentiation	 of	 C.	 albicans	 from	 other	 pathogenic	 yeasts	 in	 single	 and	 mixed	 species	
cultures,	 substantially	 improving	 in	 vitro	 detection	methods	 using	mycological	 culture.	 In	
future,	the	MAb	will	be	incorporated	into	the	rapid,	point-of-care	lateral-flow	device	(LFD)	
diagnostic	format,	previously	used	successfully	in	the	detection	of	invasive	aspergillosis	(IA).	





































































Invasive	 candidiasis;	 WT,	 wild-type;	 MAb,	 monoclonal	 antibody;	 Ig,	 immunoglobin;	 Mn,	
mannan	antigen;	A-Mn,	anti-mannan	antibody;	LFD,	lateral-flow	device;	ELISA,	enzyme-linked	
immunosorbent	assay;	PTA,	plate	trapped	antigen;	 IA,	 invasive	aspergillosis;	 ICU,	 intensive	
care	 unit;	 SDA,	 sabouraud	dextrose	 agar;	GPYA,	 glucose-peptone-yeast	 extract	 agar;	 PDA,	
potato	 dextrose	 agar;	 PBS,	 phosphate	 buffered	 saline;	 BSA,	 Bovine	 Serum	Albumin;	 TCM,	





















may	 facilitate	 fungal	 overgrowth	and	 lead	 to	 superficial	 infections,	 such	as	oropharyngeal	








of	 the	 blood)	 and	 deep-seated	 candidiasis	 (infection	 of	 the	 tissue	 sites	 beneath	mucosal	
surfaces)	(Clancy	and	Nguyen,	2013).	IC	has	only	become	a	significant	health	concern	in	the	
last	 fifty	 years,	 as	 medical	 advancements	 have	 led	 to	 a	 greater	 number	 of	 solid-organ	











body,	 so	exogenous	and	endogenous	 infections	both	pose	a	 significant	 threat	 to	high	 risk	






to	disseminate,	they	are	able	to	 infect	almost	every	organ	 in	the	body,	 leading	to	death	 if	
undiagnosed	and	untreated	(Ylipalosaari	et	al.,	2012).	Endogenous	Candida	can	cause	IC	when	
damages	 to	 the	 normal	 anatomical	 barrier	 of	 the	GI	mucosa,	 as	 a	 result	 of	GI	 surgery	 or	
aggressive	 chemotherapy,	 allow	 the	 yeast	 to	 penetrate	 deeper	 tissues	 and/or	 the	 blood	
(Vincent	et	al.,	2014).	Chemotherapy	may	also	induce	neutropenia,	while	immunosuppression	
of	 solid-organ	 or	 haematological	 stem	 cell	 transplant	 patients	 reduces	 the	 ability	 of	 the	
immune	 system	 to	 recognise	 and	 clear	Candida	 cells,	 increasing	 the	 chances	 and	 ease	 of	
infection	(Ascioglu	et	al.,	2002;	Bodey	et	al.,	2002;	Safdar	and	Armstrong,	2011).		
IC	is	the	third	most	frequent	nosocomial	infection	and	the	fourth	most	common	bloodstream	
infection,	behind	 staphylococci	 and	enterococci,	 although	 it	 carries	much	higher	mortality	
rates	 (Arendrup	 et	 al.,	 2005;	 Lewis,	 2009;	 Marchetti	 et	 al.,	 2004;	 Richet	 et	 al.,	 2002;	
Wisplinghoff	et	al.,	2004).	In	the	US	there	are	a	reported	63,000	new	cases	of	IC	each	year,	
with	 an	estimated	 financial	 cost	 of	 $1.7	billion	 (Calderone	&	Clancy,	 2011;	Morgan	et	 al.,	




2007).	 Viable	 Candida	 cells	 are	 rapidly	 eliminated	 from	 the	 circulation	 and	 so	 the	
concentration	in	the	sample	may	be	too	low	for	a	positive	identification	(Pfeiffer	et	al.,	2011;	
Schell	et	al.,	2012).	Culture	sensitivity	for	candidemia	alone	ranges	from	63%	-	83%,	but	deep-

















1998;	 Sendid	 et	 al.,	 1999).	 The	 specificities	 and	 sensitivities	 of	 the	 individual	 assays	 are	
improved	when	in	combination,	but	specificity	still	ranges	from	21%	-	95%	(Ellis	et	al.,	2009;	
Sendid	et	al.,	1999)	and	the	improved	sensitivity,	of	>71%,	decreases	significantly	for	many	




A	 “pan-fungal”	 test	 successfully	 detects	 fungal	 (1→3)-β-D-glucan,	 but	 lacks	 specificity	 to	
Candida	and	cross-reacts	with	a	number	of	yeasts	and	moulds,	 including	Trichosporon	and	
Aspergillus	species	(Karageorgopoulos	et	al.,	2011;	Pickering	et	al.,	2005).	False-positives	can	



















of	 vulnerable	 patients	 who	 have	 an	 elevated	 risk	 of	 infection,	 such	 as	 those	 with	


















and	 placed	 at	 -20	 oC	 for	 long	 term	 storage.	 Immunogen	 was	 prepared	 by	 re-suspending	
lyophilised	cells	in	sterile	filtered	phosphate	buffered	saline	(PBS;	137	mM	NaCl,	2.7	mM	KCl,	
8	mM	Na2HPO4,	and	1.5	mM	KH2PO4	[pH	7.2])	and	2	mg/mL	suspensions	heat-inactivated	by	
placing	 at	 55	 oC	 for	 45	 min.	 The	 immunogen	 was	 stored	 at	 -20	 oC	 before	 animal	































































































a	CBS;	Centraalbureau	voor	Schimmelcultures,	Utrecht,	The	Netherlands.	 SK;	 S.	Krappman,	 Institute	of	Microbiology	and	














Sigma)	 substrate	 solution	 for	 30	min,	 following	 three	PBST	and	one	PBS	5	min	wash.	 The	
reactions	were	stopped	by	the	addition	of	3	M	H2SO4.	Absorbance	values	were	determined	at	
450	nm	using	a	microplate	reader	(Tecan	GENios,	Tecan	Austria	GmbH).	Control	wells	were	
incubated	 with	 tissue	 culture	 medium	 (TCM)	 containing	 10%	 foetal	 bovine	 serum.	 All	






antigen-coated	 microtitre	 plates	 were	 incubated	 with	 hybridoma	 supernatant	 for	 1	 h,	
followed	by	goat	anti-mouse	IgG1,	IgG2a,	IgG2b,	IgG3,	IgM	or	IgA-specific	antiserum	(ISO-2;	
Sigma)	diluted	1	in	3000	in	PBST	for	30	min	and	rabbit	anti-goat	peroxidase	conjugate	diluted	
1	 in	 1000	 (A-5420;	 Sigma)	 for	 a	 further	 30	min.	Bound	antibody	was	 visualised	with	 TMB	
substrate	as	described	above.	Hybridoma	cell	lines	were	sub-cloned	three	times	by	limiting	




obtained	from	the	National	 Institute	 for	Biological	Standards	and	Control	 (NIBSC;	76/515).	



















alkaline	 phosphatase	 conjugate,	 diluted	 1	 in	 15,000	 in	 PBSA	 (IgG	whole	molecule,	 Sigma;	
A3562).	Membranes	were	washed	three	times	with	PBS,	once	with	PBST	and	bound	antibody	






at	 14,500	 rpm	 and	 the	 supernatant	 protein	 concentrations,	 determined	







of	 C.	 albicans	 were	 grown	 on	 SDA	 plates	 and	 surface	 washed	 to	 generate	 yeast	 cell	
suspensions.	 After	 washing	 with	 sterile	 MQ-H2O,	 cell	 suspensions	 were	 adjusted	 to	 103	
cells/mL,	 before	 1	 mL	 was	 added	 to	 100	 mL	 autoclaved	 GPY	 media	 (glucose	 40	 gL-1,	
bacteriological	peptone	5	gL-1,	yeast	extract	5	gL-1).	The	cultures	were	shaken	at	125	rpm	at	
26	 oC	 and	 1	 mL	 samples	 taken	 every	 24	 h	 for	 5	 days,	 centrifuged	 at	 14,500	 rpm	 and	











microtitre	 plates	 for	 assay	 by	 ELISA	 as	 described.	 To	 determine	whether	 the	 epitope	was	
present	 on	O-	 or	 N-linked	 glycans,	microtitre	wells	 containing	 immobilised	 antigens	were	
incubated	with	either	50	µL	of	50	mM	NaOH	or	50	µL	H2O	for	24h	at	room	temperature	in	
sealed	plastic	bags.	Plates	were	given	three	3	min	PBS	washes	before	assaying	by	ELISA	as	









Microscope	 slides	 were	 sterilised	 and	 coated	 with	 washed	 Candida	 albicans	 yeast	 cells	
suspended	in	1%	D-glucose	and	3%	FBS	and	incubated	at	26	oC	for	16	h.	After	air-drying,	the	
slides	 were	 fixed	 (Thornton,	 2001)	 and	 incubated	 with	 hybridoma	 supernatant	 for	 1	 h,	



























react	 with	 a	 wide	 range	 of	 other	 clinically	 relevant	 fungi,	 including	 the	 invasive	 human	
pathogens	 Cryptococcus	 neoformans	 and	 Aspergillus	 fumigatus	 (Figure	 1)	 (Dagenais	 and	
Keller,	 2009;	 Eisenman	 et	 al.,	 2008).	 The	 only	 cross-reactivity	 was	 noted	 with	 the	 yeast	

















albicans	 cell	 wall	 mannans	 at	 concentrations	 as	 low	 as	 ≥1.3	 µg/mL	 in	 ELISA	 (absorbance	

















Extensive	 literature	on	 the	properties	 of	C.	 albicans	mannan	mutants	 has	been	published	
elsewhere	(Bates	et	al.,	2005;	Hall	and	Gow,	2013;	Munro	et	al.,	2005;	Shahana	et	al.,	2013).	
In	summary,	the	mutant	Δoch1	has	no	branched	outer	chain	N-mannan,	mutant	Δmnn4	lacks	
phosphomannan	on	 the	N-branched	chain	and	mutant	Δmnt1,2	 has	 truncated	O-mannan.	
Δpmr1	 differs	 in	 that	 disruption	 of	 the	 PMR1	 gene	 reduces	 the	 activity	 of	 all	 the	
mannosyltransferases	mentioned	above,	along	with	many	others,	resulting	in	truncation	of	
all	branched	N-mannan,	O-mannan	and	PLM	structures	 (Bates	et	al.,	 2005;	Hall	 and	Gow,	
2013;	Munro	et	al.,	2005).	MAb	MC3	reacted	with	all	 four	mutant	strains	of	C.	albicans	 in	
ELISA	 tests	 and	 no	 significant	 differences	 in	 absorbance	 values	 were	 noted	 despite	 the	
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blot	 conducted	 with	 the	 same	 samples	 showed	 that	 MAb	 MC3	 reacted	 strongly	 with	
extracellular	mannan	antigens	(Figure	2F).	The	staining	pattern	with	Δpmr1	signified	severely	
truncated	 mannosylation	 of	 the	 extracellular	 antigen	 (Figure	 2F).	 With	 the	 exception	 of	




Candida	 albicans	 SC5314	 antigens	were	 subjected	 to	 different	 heat	 (Figure	 2G),	 chemical	
(Figure	2H)	and	enzymatic	(Table	2)	modifications	in	order	to	further	characterise	the	epitope	
bound	by	MAb	MC3.	Reductions	 in	MAb	binding	 in	ELISA	 following	heat	 treatment	would	
show	that	an	epitope	is	heat	labile.	There	was	no	significant	reduction	in	MAb	MC3	binding	
over	60	mins	of	heating,	revealing	that	its	epitope	is	heat-stable	(Figure	2G).	Reductions	in	
MAb	 binding	 following	 treatment	 with	 pronase	 would	 show	 that	 the	 epitope	 consists	 of	














 Absorbance  (450 nma) 
Temp (oC) Trypsin H2O Pronase PBS 
4 1.366 ±	0.018 1.457 ± 0.010 1.313 ± 0.014 1.438 ± 0.013 











Figure	2	Characterisation	of	antigens	bound	by	MAb	MC3.	 (A)	 ELISA	absorbance	 values	 for	MAb	MC3	
recognition	of	purified	C.	albicans	cell	wall	mannans.	(B)	Western	immunoblot	with	MAb	MC3	of	purified	C.	albicans	cell	wall	
mannan	(lane	2)	and	C.	albicans	SC5314	antigens	(lane	3).	Mr	(lane	1)	is	broad	range	molecular	weight	markers.	(C)	ELISA	












































































most	 medically	 relevant	 Candida	 species,	 are	 very	 closely	 related	 and	 have	 a	 high	
conservation	of	protein-coding	genes,	with	all	members	translating	the	CTG	codon	as	serine	
instead	of	leucine	(Santos	and	Tuite,	1995;	Santos	et	al.,	2011).	The	high	similarity	between	
members	 of	 the	 clade	 has	 led	 to	 several	 previously	 unknown	 species	 being	 unmasked.	
Candida	 palmioleophila,	 for	 example,	 was	 discovered	 within	 the	 phenotypically	
indistinguishable	 Candida	 guilliermondii	 grouping	 (Jensen	 and	 Arendrup,	 2011),	 while	
Candida	orthopsilosis	and	Candida	metapsilosis	have	replaced	Candida	parapsilosis	groups	II	
and	III,	respectively	(Tavanti	et	al.,	2005).	
Antigen	 characterisation	 studies	 showed	MAb	MC3	 to	be	 specific	 to	 cell	wall	mannans	of	
Candida	 albicans	 yeast,	 pseudohyphal	 and	 hyphal	morphotypes.	 This	 is	 important	 from	 a	
diagnostic	 perspective	 since	 C.	 albicans	 is	 a	 pleomorphic	 yeast,	 which	 regularly	 switches	
morphologies	during	 infection	 (Calderone	and	Fonzi,	2001;	Staniszewska	et	al.,	2012).	The	
apparent	 recognition	 of	 PLM	 (demonstrated	 by	 absence	 of	 the	 ~10	 kDa	 immunoreactive	
antigen	in	the	PLM	mutant	Δpmr1)	suggests	that	the	MC3	epitope	consists	of	β-1,2-mannan	
residues	 (Fradin	et	al.,	 2008;	Mille	et	al.,	 2004;	Trinel	et	al.,	 1999).	This	 is	 consistent	with	
immunodominant	(1→2)-β-mannan	structures	in	C.	albicans	PLM	bound	by	the	protective	β-
mannan-specific	IgG3	MAb,	C3.1	(Han	et	al.,	2000;	Johnson	et	al.,	2012).	The	staining	pattern	

















chemotherapies	 (Krcmery	 and	Barnes,	 2002;	Wingard,	 1995),	 and	Candida	 orthopsilosis	 is	
commonly	 associated	 with	 nosocomial	 infections	 (Barbedo	 et	 al.,	 2014).	 Candida	
guilliermondii	and	Candida	dubliniensis,	while	less	widespread,	are	becoming	more	common	
as	causes	of	IC	(Brandt	et	al.;	Krcmery	and	Barnes,	2002;	Pfaller	et	al.,	2006).	MAb	MC3	also	
displayed	 cross-reactivity	 with	 Rhodosporidium	 toruloides,	 but	 this	 yeast	 has	 not	 been	
reported	as	a	cause	of	invasive	fungal	infection	in	humans.	






profiles.	 The	 azole	 drug	 fluconazole	 is	 the	most	 widely	 used	 Candida-active	 antifungal	 in	
clinical	practice	(Pappas	et	al.,	2009),	and	C.	parapsilosis	(Sarvikivi	et	al.,	2005),	C.	glabrata	
(Panackal	et	al.,	2006;	Sanguinetti	et	al.,	2005),and	C.	krusei	(Espinel-Ingroff	et	al.,	2014)	all	







the	 drugs	most	 widely	 used	 in	 clinical	 practice	 (Pappas	 et	 al.,	 2009;	 Pfaller	 et	 al.,	 2010).	
Detection	of	infection	by	MC3-reactive	species,	for	example	through	use	in	an	ELISA	or	LFD,	
would	 therefore	 allow	 effective	 antifungal	 treatment	 to	 be	 delivered	 immediately,	 with	
confidence	of	drug	efficacy.	Test	negativity	would	indicate	infection	by	alternative	species,	
requiring	 blood	 culture	 and	 drug	 resistance	 profiling	 	 (Jones,	 1990;	 Pfaller	 and	 Diekema,	
2007).	
Non-invasive,	 non-culture	 based	 serodiagnostic	 tests	 are	 already	 used	 in	 clinical	 practice.	
Combined	 determination	 of	 Mn	 and	 A-Mn	 using	 the	 Platelia	 Candida	 ELISA	 formats,	 for	
example,	has	become	a	useful	aid	in	monitoring	patients	at	high	risk	for	IC	(Mikulska	et	al.,	
2010).	The	previously	discussed	limitations	of	the	assay,	however,	hamper	its	effectiveness	
and	 few	 prospective	 evaluating	 studies	 have	 been	 conducted	 thus	 far	 (Ellis	 et	 al.,	 2009;	
Mikulska	et	al.,	2010).	Moreover,	the	genus	specific	test	does	not	give	an	indication	of	which	
Candida	 species	 may	 be	 causing	 the	 IC,	 which	 could	 present	 difficulties	 in	 choosing	 an	
appropriate	treatment	strategy	due	to	the	potential	for	antifungal	resistance	(Pappas	et	al.,	









moulds,	 including	Trichosporon	and	Aspergillus	species,	so	 its	use	 in	detecting	 IC	 is	 limited	
(Karageorgopoulos	et	al.,	2011;	Pickering	et	al.,	2005).	Nonetheless,	the	test	does	serve	as	
broad	marker	 of	 invasive	 fungal	 infection,	which	may	 be	 caused	 by	 a	 single	 species,	 or	 a	
combination	of	different	species	(Yang	et	al.,	2014).	
Combinations	of	different	fungal	species	causing	mixed	yeast	infections	in	high	risk	patient	









issues,	 antigen	 solutions	 from	 mixed	 cultures	 of	 Candida	 albicans,	 Candida	 glabrata,	
Trichosporon	asahii	and	Cryptococcus	neoformans,	grown	on	SDA	plates,	were	tested	in	ELISA	
using	MAb	MC3.	The	antibody	allowed	unambiguous	identification	of	Candida	albicans	when	






range	 of	 related	 and	 unrelated	 clinically-relevant	 yeasts	 and	moulds.	 The	MAb	 has	 been	
shown	to	improve	the	diagnostic	accuracy	of	mycological	cultures	employing	a	standardised	
growth	medium,	through	use	in	a	highly	specific	ELISA.	The	MAb	was	specific	to	a	mannan	
antigen	 released	 extracellularly	 by	 C.	 albicans,	 which	might	 translate	 to	 the	 detection	 of	
released	circulating	antigens	 in	the	bloodstream	of	 IC	patients	(Clancy	and	Nguyen,	2013).	
However,	patient	sera	must	be	tested	to	confirm	that	MC3	is	able	to	detect	these	Candida	













to	 those	using	 the	Mn/A-Mn	and	 (1→3)-β-D-glucan	 tests.	An	 LFD	 format	would	provide	a	
rapid	point-of-care	diagnostic	platform	that	is	inexpensive,	non-invasive	and	requires	minimal	
training	for	use.	
Acknowledgements	
The	author	would	like	to	thank	Christopher.	R.	Thornton	for	guidance	in	compiling	this	
report	and	Christopher.	R.	Thornton	and	Genna	E.	Davies	for	laboratory	support.	
References	
Alexander,	B.D.,	Johnson,	M.D.,	Pfeiffer,	C.D.,	Jiménez-Ortigosa,	C.,	Catania,	J.,	Booker,	R.,	
Castanheira,	M.,	Messer,	S.A.,	Perlin,	D.S.,	Pfaller,	M.A.,	2013.	Increasing	echinocandin	
resistance	in	Candida	glabrata:	clinical	failure	correlates	with	presence	of	FKS	
mutations	and	elevated	minimum	inhibitory	concentrations.	Clin.	Infect.	Dis.	56,	1724–
32.	
Alexander,	B.D.,	Smith,	P.B.,	Davis,	R.D.,	Perfect,	J.R.,	Reller,	L.B.,	2010.	The	(1,3){beta}-D-
glucan	test	as	an	aid	to	early	diagnosis	of	invasive	fungal	infections	following	lung	
transplantation.	J.	Clin.	Microbiol.	48,	4083–8.	
Ang,	B.S.,	Telenti,	A.,	King,	B.,	Steckelberg,	J.M.,	Wilson,	W.R.,	1993.	Candidemia	from	a	
urinary	tract	source:	microbiological	aspects	and	clinical	significance.	Clin.	Infect.	Dis.	
17,	662–6.	
Arendrup,	M.C.,	Fuursted,	K.,	Gahrn-Hansen,	B.,	Jensen,	I.M.,	Knudsen,	J.D.,	Lundgren,	B.,	
Schønheyder,	H.C.,	Tvede,	M.,	2005.	Seminational	surveillance	of	fungemia	in	
Denmark:	notably	high	rates	of	fungemia	and	numbers	of	isolates	with	reduced	azole	
susceptibility.	J.	Clin.	Microbiol.	43,	4434–40.	
Ascioglu,	S.,	Rex,	J.H.,	de	Pauw,	B.,	Bennett,	J.E.,	Bille,	J.,	Crokaert,	F.,	Denning,	D.W.,	
Donnelly,	J.P.,	Edwards,	J.E.,	Erjavec,	Z.,	Fiere,	D.,	Lortholary,	O.,	Maertens,	J.,	Meis,	J.F.,	
Patterson,	T.F.,	Ritter,	J.,	Selleslag,	D.,	Shah,	P.M.,	Stevens,	D.A.,	Walsh,	T.J.,	2002.	
Defining	opportunistic	invasive	fungal	infections	in	immunocompromised	patients	with	
cancer	and	hematopoietic	stem	cell	transplants:	an	international	consensus.	Clin.	
Infect.	Dis.	34,	7–14.	
29	
	
Avni,	T.,	Leibovici,	L.,	Paul,	M.,	2011.	PCR	diagnosis	of	invasive	candidiasis:	systematic	review	
and	meta-analysis.	J.	Clin.	Microbiol.	49,	665–70.	
Badiye,	A.,	Patnaik,	M.,	Deshpande,	A.,	Rajendran,	C.,	Chandrashekara,	K.	V,	2012.	Think	
fungus	NOT	just	a	crypto-meningitis	in	AIDS!	J.	Assoc.	Physicians	India	60,	21–4.	
Bailey,	J.W.,	Sada,	E.,	Brass,	C.,	Bennett,	J.E.,	1985.	Diagnosis	of	systemic	candidiasis	by	latex	
agglutination	for	serum	antigen.	J.	Clin.	Microbiol.	21,	749–752.	
Barbedo,	L.S.,	Vaz,	C.,	Pais,	C.,	Figueiredo-Carvalho,	M.H.G.,	Muniz,	M.	d.	M.,	Zancope-
Oliveira,	R.M.,	Sampaio,	P.,	2014.	Different	scenarios	for	Candida	parapsilosis	
fungaemia	reveal	high	numbers	of	mixed	C.	parapsilosis	and	Candida	orthopsilosis	
infections.	J.	Med.	Microbiol.	64,	7–17.	
Bassetti,	M.,	Righi,	E.,	Ansaldi,	F.,	Merelli,	M.,	Trucchi,	C.,	Cecilia,	T.,	De	Pascale,	G.,	Diaz-
Martin,	A.,	Luzzati,	R.,	Rosin,	C.,	Lagunes,	L.,	Trecarichi,	E.M.,	Sanguinetti,	M.,	
Posteraro,	B.,	Garnacho-Montero,	J.,	Sartor,	A.,	Rello,	J.,	Rocca,	G.	Della,	Antonelli,	M.,	
Tumbarello,	M.,	2014.	A	multicenter	study	of	septic	shock	due	to	candidemia:	
outcomes	and	predictors	of	mortality.	Intensive	Care	Med.	40,	839–45.	
Bates,	S.,	MacCallum,	D.M.,	Bertram,	G.,	Munro,	C.A.,	Hughes,	H.B.,	Buurman,	E.T.,	Brown,	
A.J.P.,	Odds,	F.C.,	Gow,	N.A.R.,	2005.	Candida	albicans	Pmr1p,	a	secretory	pathway	P-
type	Ca2+/Mn2+-ATPase,	is	required	for	glycosylation	and	virulence.	J.	Biol.	Chem.	280,	
23408–15.	
Bodey,	G.P.,	Mardani,	M.,	Hanna,	H.A.,	Boktour,	M.,	Abbas,	J.,	Girgawy,	E.,	Hachem,	R.Y.,	
Kontoyiannis,	D.P.,	Raad,	I.I.,	2002.	The	epidemiology	of	Candida	glabrata	and	Candida	
albicans	fungemia	in	immunocompromised	patients	with	cancer.	Am.	J.	Med.	112,	380–
385.	
Brandt,	M.E.,	Harrison,	L.H.,	Pass,	M.,	Sofair,	A.N.,	Huie,	S.,	Li,	R.K.,	Morrison,	C.J.,	Warnock,	
D.W.,	Hajjeh,	R.A.,.	Candida	dubliniensis	fungemia:	the	first	four	cases	in	North	
America.	Emerg.	Infect.	Dis.	6,	46–9.	
Butler,	G.,	Rasmussen,	M.D.,	Lin,	M.F.,	Santos,	M.A.S.,	Sakthikumar,	S.,	Munro,	C.A.,	
Rheinbay,	E.,	Grabherr,	M.,	Forche,	A.,	Reedy,	J.L.,	Agrafioti,	I.,	Arnaud,	M.B.,	Bates,	S.,	
Brown,	A.J.P.,	Brunke,	S.,	Costanzo,	M.C.,	Fitzpatrick,	D.A.,	de	Groot,	P.W.J.,	Harris,	D.,	
Hoyer,	L.L.,	Hube,	B.,	Klis,	F.M.,	Kodira,	C.,	Lennard,	N.,	Logue,	M.E.,	Martin,	R.,	Neiman,	
30	
	
A.M.,	Nikolaou,	E.,	Quail,	M.A.,	Quinn,	J.,	Santos,	M.C.,	Schmitzberger,	F.F.,	Sherlock,	
G.,	Shah,	P.,	Silverstein,	K.A.T.,	Skrzypek,	M.S.,	Soll,	D.,	Staggs,	R.,	Stansfield,	I.,	Stumpf,	
M.P.H.,	Sudbery,	P.E.,	Srikantha,	T.,	Zeng,	Q.,	Berman,	J.,	Berriman,	M.,	Heitman,	J.,	
Gow,	N.A.R.,	Lorenz,	M.C.,	Birren,	B.W.,	Kellis,	M.,	Cuomo,	C.A.,	2009.	Evolution	of	
pathogenicity	and	sexual	reproduction	in	eight	Candida	genomes.	Nature	459,	657–62.	
Calderone	&	Clancy,	2011.	Candida	and	Candidiasis.	American	Society	for	Microbiology	
Press.	
Calderone,	R.A.,	Fonzi,	W.A.,	2001.	Virulence	factors	of	Candida	albicans.	Trends	Microbiol.	
9,	327–335.	
Cantón,	E.,	Pemán,	J.,	Quindós,	G.,	Eraso,	E.,	Miranda-Zapico,	I.,	Álvarez,	M.,	Merino,	P.,	
Campos-Herrero,	I.,	Marco,	F.,	de	la	Pedrosa,	E.G.G.,	Yagüe,	G.,	Guna,	R.,	Rubio,	C.,	
Miranda,	C.,	Pazos,	C.,	Velasco,	D.,	2011.	Prospective	multicenter	study	of	the	
epidemiology,	molecular	identification,	and	antifungal	susceptibility	of	Candida	
parapsilosis,	Candida	orthopsilosis,	and	Candida	metapsilosis	isolated	from	patients	
with	candidemia.	Antimicrob.	Agents	Chemother.	55,	5590–6.	
Chi,	H.-W.,	Yang,	Y.-S.,	Shang,	S.-T.,	Chen,	K.-H.,	Yeh,	K.-M.,	Chang,	F.-Y.,	Lin,	J.-C.,	2011.	
Candida	albicans	versus	non-albicans	bloodstream	infections:	the	comparison	of	risk	
factors	and	outcome.	J.	Microbiol.	Immunol.	Infect.	44,	369–75.	
Clancy,	C.J.,	Nguyen,	M.H.,	2013.	Finding	the	“missing	50%”	of	invasive	candidiasis:	how	
nonculture	diagnostics	will	improve	understanding	of	disease	spectrum	and	transform	
patient	care.	Clin.	Infect.	Dis.	56,	1284–92.	
Cole,	G.T.,	Halawa,	A.A.,	Anaissie,	E.J.,	1996.	The	role	of	the	gastrointestinal	tract	in	
hematogenous	candidiasis:	from	the	laboratory	to	the	bedside.	Clin.	Infect.	Dis.	22	
Suppl	2,	S73–88.	
Dagenais,	T.R.T.,	Keller,	N.P.,	2009.	Pathogenesis	of	Aspergillus	fumigatus	in	Invasive	
Aspergillosis.	Clin.	Microbiol.	Rev.	22,	447–465.	
de	Repentigny,	L.,	Lewandowski,	D.,	Jolicoeur,	P.,	2004.	Immunopathogenesis	of	
oropharyngeal	candidiasis	in	human	immunodeficiency	virus	infection.	Clin.	Microbiol.	
Rev.	17,	729–59.	
Diekema,	D.,	Arbefeville,	S.,	Boyken,	L.,	Kroeger,	J.,	Pfaller,	M.,	2012.	The	changing	
31	
	
epidemiology	of	healthcare-associated	candidemia	over	three	decades.	Diagn.	
Microbiol.	Infect.	Dis.	73,	45–8.	
Eisenman,	H.C.,	Casadevall,	A.,	McClelland,	E.E.,	2008.	New	insights	on	the	pathogenesis	of	
invasive	Cryptococcus	neoformans	infection.	Curr.	Infect.	Dis.	Rep.	9,	457–464.	
Ellis,	M.,	Al-Ramadi,	B.,	Bernsen,	R.,	Kristensen,	J.,	Alizadeh,	H.,	Hedstrom,	U.,	2009.	
Prospective	evaluation	of	mannan	and	anti-mannan	antibodies	for	diagnosis	of	invasive	
Candida	infections	in	patients	with	neutropenic	fever.	J.	Med.	Microbiol.	58,	606–15.	
Espinel-Ingroff,	A.,	Pfaller,	M.A.,	Bustamante,	B.,	Canton,	E.,	Fothergill,	A.,	Fuller,	J.,	
Gonzalez,	G.M.,	Lass-Flörl,	C.,	Lockhart,	S.R.,	Martin-Mazuelos,	E.,	Meis,	J.F.,	Melhem,	
M.S.C.,	Ostrosky-Zeichner,	L.,	Pelaez,	T.,	Szeszs,	M.W.,	St-Germain,	G.,	Bonfietti,	L.X.,	
Guarro,	J.,	Turnidge,	J.,	2014.	Multilaboratory	study	of	epidemiological	cutoff	values	for	
detection	of	resistance	in	eight	Candida	species	to	fluconazole,	posaconazole,	and	
voriconazole.	Antimicrob.	Agents	Chemother.	58,	2006–12.	
Fidel,	P.L.,	2006.	Candida-Host	Interactions	in	HIV	Disease:	Relationships	in	Oropharyngeal	
Candidiasis.	Adv.	Dent.	Res.	19,	80–84.	
Forrest,	G.N.,	Weekes,	E.,	Johnson,	J.K.,	2008.	Increasing	incidence	of	Candida	parapsilosis	
candidemia	with	caspofungin	usage.	J.	Infect.	56,	126–9.	
Fradin,	C.,	Slomianny,	M.C.,	Mille,	C.,	Masset,	A.,	Robert,	R.,	Sendid,	B.,	Ernst,	J.F.,	Michalski,	
J.C.,	Poulain,	D.,	2008.	Beta-1,2	oligomannose	adhesin	epitopes	are	widely	distributed	
over	the	different	families	of	Candida	albicans	cell	wall	mannoproteins	and	are	
associated	through	both	N-	and	O-glycosylation	processes.	Infect.	Immun.	76,	4509–17.	
Garey,	K.W.,	Rege,	M.,	Pai,	M.P.,	Mingo,	D.E.,	Suda,	K.J.,	Turpin,	R.S.,	Bearden,	D.T.,	2006.	
Time	to	initiation	of	fluconazole	therapy	impacts	mortality	in	patients	with	candidemia:	
a	multi-institutional	study.	Clin.	Infect.	Dis.	43,	25–31.	
Gow,	N.A.R.,	van	de	Veerdonk,	F.L.,	Brown,	A.J.P.,	Netea,	M.G.,	2012.	Candida	albicans	
morphogenesis	and	host	defence:	discriminating	invasion	from	colonization.	Nat.	Rev.	
Microbiol.	10,	112–22.	
Gudlaugsson,	O.,	Gillespie,	S.,	Lee,	K.,	Vande	Berg,	J.,	Hu,	J.,	Messer,	S.,	Herwaldt,	L.,	Pfaller,	
M.,	Diekema,	D.,	2003.	Attributable	mortality	of	nosocomial	candidemia,	revisited.	Clin.	
Infect.	Dis.	37,	1172–7.	
32	
	
Guinea,	J.,	2014.	Global	trends	in	the	distribution	of	Candida	species	causing	candidemia.	
Clin.	Microbiol.	Infect.	20	Suppl	6,	5–10.	
Hakki,	M.,	Staab,	J.F.,	Marr,	K.A.,	2006.	Emergence	of	a	Candida	krusei	isolate	with	reduced	
susceptibility	to	caspofungin	during	therapy.	Antimicrob.	Agents	Chemother.	50,	2522–
4.	
Hall,	R.A.,	Gow,	N.A.R.,	2013.	Mannosylation	in	Candida	albicans:	role	in	cell	wall	function	
and	immune	recognition.	Mol.	Microbiol.	90,	1147–61.	
Han,	Y.,	Riesselman,	M.H.,	Cutler,	J.E.,	2000.	Protection	against	candidiasis	by	an	
immunoglobulin	G3	(IgG3)	monoclonal	antibody	specific	for	the	same	mannotriose	as	
an	IgM	protective	antibody.	Infect.	Immun.	68,	1649–54.	
Held,	J.,	Schmidt,	T.,	Thornton,	C.R.,	Kotter,	E.,	Bertz,	H.,	2013.	Comparison	of	a	novel	
Aspergillus	lateral-flow	device	and	the	Platelia®	galactomannan	assay	for	the	diagnosis	
of	invasive	aspergillosis	following	haematopoietic	stem	cell	transplantation.	Infection	
41,	1163–9.	
Jacquinot,	P.M.,	Plancke,	Y.,	Sendid,	B.,	Strecker,	G.,	Poulain,	D.,	1998.	Nature	of	Candida	
albicans-derived	carbohydrate	antigen	recognized	by	a	monoclonal	antibody	in	patient	
sera	and	distribution	over	Candida	species.	FEMS	Microbiol.	Lett.	169,	131–8.	
Jaijakul,	S.,	Vazquez,	J.A.,	Swanson,	R.N.,	Ostrosky-Zeichner,	L.,	2012.	(1,3)-β-D-glucan	as	a	
prognostic	marker	of	treatment	response	in	invasive	candidiasis.	Clin.	Infect.	Dis.	55,	
521–6.	
Jensen,	R.H.,	Arendrup,	M.C.,	2011.	Candida	palmioleophila:	characterization	of	a	previously	
overlooked	pathogen	and	its	unique	susceptibility	profile	in	comparison	with	five	
related	species.	J.	Clin.	Microbiol.	49,	549–56.	
Johnson,	M.,	Cartmell,	J.,	Weisser,	N.,	2012.	Molecular	recognition	of	Candida	albicans	(1→	
2)-β-mannan	oligosaccharides	by	a	protective	monoclonal	antibody	reveals	the	
immunodominance	of	internal.	J.	Biol.	Chem.	287,	18078–90.	
Jones,	J.M.,	1990.	Laboratory	diagnosis	of	invasive	candidiasis.	Clin.	Microbiol.	Rev.	3,	32–45.	
Jouault,	T.,	Fradin,	C.,	Trinel,	P.	a,	Bernigaud,		a,	Poulain,	D.,	1998.	Early	signal	transduction	
induced	by	Candida	albicans	in	macrophages	through	shedding	of	a	glycolipid.	J.	Infect.	
33	
	
Dis.	178,	792–802.	
Kahn,	J.N.,	Garcia-Effron,	G.,	Hsu,	M.-J.,	Park,	S.,	Marr,	K.A.,	Perlin,	D.S.,	2007.	Acquired	
echinocandin	resistance	in	a	Candida	krusei	isolate	due	to	modification	of	glucan	
synthase.	Antimicrob.	Agents	Chemother.	51,	1876–8.	
Karageorgopoulos,	D.E.,	Vouloumanou,	E.K.,	Ntziora,	F.,	Michalopoulos,	A.,	Rafailidis,	P.I.,	
Falagas,	M.E.,	2011.	β-D-glucan	assay	for	the	diagnosis	of	invasive	fungal	infections:	a	
meta-analysis.	Clin.	Infect.	Dis.	52,	750–70.	
Kedzierska,	A.,	Kochan,	P.,	Pietrzyk,	A.,	Kedzierska,	J.,	2007.	Current	status	of	fungal	cell	wall	
components	in	the	immunodiagnostics	of	invasive	fungal	infections	in	humans:	
galactomannan,	mannan	and	(1-->3)-beta-D-glucan	antigens.	Eur.	J.	Clin.	Microbiol.	
Infect.	Dis.	26,	755–66.	
Klis,	F.M.,	1994.	Review:	cell	wall	assembly	in	yeast.	Yeast	10,	851–69.	
Kojic,	E.M.,	Darouiche,	R.O.,	2004.	Candida	Infections	of	Medical	Devices.	Clin.	Microbiol.	
Rev.	17,	255–267.	
Krcmery,	V.,	Barnes,	A.J.,	2002.	Non-albicans	Candida	spp.	causing	fungaemia:	pathogenicity	
and	antifungal	resistance.	J.	Hosp.	Infect.	50,	243–60.	
Lamoth,	F.,	Cruciani,	M.,	Mengoli,	C.,	Castagnola,	E.,	Lortholary,	O.,	Richardson,	M.,	
Marchetti,	O.,	2012.	β-Glucan	antigenemia	assay	for	the	diagnosis	of	invasive	fungal	
infections	in	patients	with	hematological	malignancies:	a	systematic	review	and	meta-
analysis	of	cohort	studies	from	the	Third	European	Conference	on	Infections	in	
Leukemia	(ECIL-3).	Clin.	Infect.	Dis.	54,	633–43.	
Leung,	A.Y.H.,	Chim,	C.S.,	Ho,	P.L.,	Cheng,	V.C.C.,	Yuen,	K.Y.,	Lie,	A.K.W.,	Au,	W.Y.,	Liang,	R.,	
Kwong,	Y.L.,	2002.	Candida	tropicalis	fungaemia	in	adult	patients	with	haematological	
malignancies:	clinical	features	and	risk	factors.	J.	Hosp.	Infect.	50,	316–9.	
Lewis,	R.E.,	2009.	Overview	of	the	changing	epidemiology	of	candidemia.	Curr.	Med.	Res.	
Opin.	25,	1732–40.	
Lucignano,	B.,	Ranno,	S.,	Liesenfeld,	O.,	Pizzorno,	B.,	Putignani,	L.,	Bernaschi,	P.,	Menichella,	
D.,	2011.	Multiplex	PCR	allows	rapid	and	accurate	diagnosis	of	bloodstream	infections	
in	newborns	and	children	with	suspected	sepsis.	J.	Clin.	Microbiol.	49,	2252–8.	
34	
	
Marchetti,	O.,	Bille,	J.,	Fluckiger,	U.,	Eggimann,	P.,	Ruef,	C.,	Garbino,	J.,	Calandra,	T.,	Glauser,	
M.-P.,	Täuber,	M.G.,	Pittet,	D.,	2004.	Epidemiology	of	candidemia	in	Swiss	tertiary	care	
hospitals:	secular	trends,	1991-2000.	Clin.	Infect.	Dis.	38,	311–20.	
Martin,	R.,	Wächtler,	B.,	Schaller,	M.,	Wilson,	D.,	Hube,	B.,	2011.	Host-pathogen	interactions	
and	virulence-associated	genes	during	Candida	albicans	oral	infections.	Int.	J.	Med.	
Microbiol.	301,	417–22.	
McMullan,	R.,	Metwally,	L.,	Coyle,	P.	V,	Hedderwick,	S.,	McCloskey,	B.,	O’Neill,	H.J.,	
Patterson,	C.C.,	Thompson,	G.,	Webb,	C.H.,	Hay,	R.J.,	2008.	A	prospective	clinical	trial	of	
a	real-time	polymerase	chain	reaction	assay	for	the	diagnosis	of	candidemia	in	
nonneutropenic,	critically	ill	adults.	Clin.	Infect.	Dis.	46,	890–6.	
Mikulska,	M.,	Calandra,	T.,	Sanguinetti,	M.,	Poulain,	D.,	Viscoli,	C.,	2010.	The	use	of	mannan	
antigen	and	anti-mannan	antibodies	in	the	diagnosis	of	invasive	candidiasis:	
recommendations	from	the	Third	European	Conference	on	Infections	in	Leukemia.	Crit.	
care	14,	R222.	
Mille,	C.,	Fradin,	C.,	Delplace,	F.,	Trinel,	P.-A.,	Masset,	A.,	François,	N.,	Coddeville,	B.,	
Bobrowicz,	P.,	Jouault,	T.,	Guerardel,	Y.,	Wildt,	S.,	Janbon,	G.,	Poulain,	D.,	2012.	
Members	5	and	6	of	the	Candida	albicans	BMT	family	encode	enzymes	acting	
specifically	on	β-mannosylation	of	the	phospholipomannan	cell-wall	glycosphingolipid.	
Glycobiology	22,	1332–42.	
Mille,	C.,	Janbon,	G.,	Delplace,	F.,	Ibata-Ombetta,	S.,	Gaillardin,	C.,	Strecker,	G.,	Jouault,	T.,	
Trinel,	P.-A.,	Poulain,	D.,	2004.	Inactivation	of	CaMIT1	inhibits	Candida	albicans	
phospholipomannan	beta-mannosylation,	reduces	virulence,	and	alters	cell	wall	
protein	beta-mannosylation.	J.	Biol.	Chem.	279,	47952–60.	
Morgan,	J.,	Meltzer,	M.I.,	Plikaytis,	B.D.,	Sofair,	A.N.,	Huie-White,	S.,	Wilcox,	S.,	Harrison,	
L.H.,	Seaberg,	E.C.,	Hajjeh,	R.A.,	Teutsch,	S.M.,	2005.	Excess	mortality,	hospital	stay,	
and	cost	due	to	candidemia:	a	case-control	study	using	data	from	population-based	
candidemia	surveillance.	Infect.	Control	Hosp.	Epidemiol.	26,	540–7.	
Morgan,	M.A.,	Wilkowske,	C.J.,	Roberts,	G.D.,	1984.	Candida	pseudotropicalis	fungemia	and	
invasive	disease	in	an	immunocompromised	patient.	J.	Clin.	Microbiol.	20,	1006–7.	
Morrell,	M.,	Fraser,	V.J.,	Kollef,	M.H.,	2005.	Delaying	the	empiric	treatment	of	candida	
35	
	
bloodstream	infection	until	positive	blood	culture	results	are	obtained:	a	potential	risk	
factor	for	hospital	mortality.	Antimicrob.	Agents	Chemother.	49,	3640–5.	
Moudgal,	V.,	Little,	T.,	Boikov,	D.,	Vazquez,	J.A.,	2005.	Multiechinocandin-	and	multiazole-
resistant	Candida	parapsilosis	isolates	serially	obtained	during	therapy	for	prosthetic	
valve	endocarditis.	Antimicrob.	Agents	Chemother.	49,	767–9.	
Munro,	C.A.,	Bates,	S.,	Buurman,	E.T.,	Hughes,	H.B.,	Maccallum,	D.M.,	Bertram,	G.,	Atrih,	A.,	
Ferguson,	M.A.J.,	Bain,	J.M.,	Brand,	A.,	Hamilton,	S.,	Westwater,	C.,	Thomson,	L.M.,	
Brown,	A.J.P.,	Odds,	F.C.,	Gow,	N.A.R.,	2005.	Mnt1p	and	Mnt2p	of	Candida	albicans	are	
partially	redundant	alpha-1,2-mannosyltransferases	that	participate	in	O-linked	
mannosylation	and	are	required	for	adhesion	and	virulence.	J.	Biol.	Chem.	280,	1051–
60.	
Ness,	M.J.,	Vaughan,	W.P.,	Woods,	G.L.,	1989.	Candida	antigen	latex	test	for	detection	of	
invasive	candidiasis	in	immunocompromised	patients.	J.	Infect.	Dis.	159,	495–502.	
Netea,	M.G.,	Brown,	G.D.,	Kullberg,	B.J.,	Gow,	N.A.R.,	2008.	An	integrated	model	of	the	
recognition	of	Candida	albicans	by	the	innate	immune	system.	Nat.	Rev.	Microbiol.	6,	
67–78.	
Obayashi,	T.,	Negishi,	K.,	Suzuki,	T.,	Funata,	N.,	2008.	Reappraisal	of	the	serum	(1-->3)-beta-
D-glucan	assay	for	the	diagnosis	of	invasive	fungal	infections--a	study	based	on	autopsy	
cases	from	6	years.	Clin.	Infect.	Dis.	46,	1864–70.	
Otero	Silva,	J.,	Franceschini,	S.A.,	Lavrador,	M.A.S.,	Candido,	R.C.,	2004.	Performance	of	
Selective	and	Differential	Media	in	the	Primary	Isolation	of	Yeasts	from	Different	
Biological	Samples.	Mycopathologia	157,	29–36.	
Panackal,	A.A.,	Gribskov,	J.L.,	Staab,	J.F.,	Kirby,	K.A.,	Rinaldi,	M.,	Marr,	K.A.,	2006.	Clinical	
significance	of	azole	antifungal	drug	cross-resistance	in	Candida	glabrata.	J.	Clin.	
Microbiol.	44,	1740–3.	
Pappas,	P.G.,	Kauffman,	C.A.,	Andes,	D.,	Benjamin,	D.K.,	Calandra,	T.F.,	Edwards,	J.E.,	Filler,	
S.G.,	Fisher,	J.F.,	Kullberg,	B.-J.,	Ostrosky-Zeichner,	L.,	Reboli,	A.C.,	Rex,	J.H.,	Walsh,	T.J.,	
Sobel,	J.D.,	2009.	Clinical	practice	guidelines	for	the	management	of	candidiasis:	2009	
update	by	the	Infectious	Diseases	Society	of	America.	Clin.	Infect.	Dis.	48,	503–35.	
Pfaller,	M.,	Houston,	A.,	Coffmann,	S.,	1996.	Application	of	CHROMagar	Candida	for	rapid	
36	
	
screening	of	clinical	specimens	for	Candida	albicans,	Candida	tropicalis,	Candida	krusei,	
and	Candida	(Torulopsis)	glabrata.	J.	Clin.	Microbiol.	34,	58–61.	
Pfaller,	M.A.,	Andes,	D.R.,	Diekema,	D.J.,	Horn,	D.L.,	Reboli,	A.C.,	Rotstein,	C.,	Franks,	B.,	
Azie,	N.E.,	2014.	Epidemiology	and	outcomes	of	invasive	candidiasis	due	to	non-
albicans	species	of	Candida	in	2,496	patients:	data	from	the	Prospective	Antifungal	
Therapy	(PATH)	registry	2004-2008.	PLoS	One	9,	e101510.	
Pfaller,	M.A.,	Diekema,	D.J.,	2007.	Epidemiology	of	invasive	candidiasis:	a	persistent	public	
health	problem.	Clin.	Microbiol.	Rev.	20,	133–63.	
Pfaller,	M.A.,	Diekema,	D.J.,	Gibbs,	D.L.,	Newell,	V.A.,	Ellis,	D.,	Tullio,	V.,	Rodloff,	A.,	Fu,	W.,	
Ling,	T.A.,	2010.	Results	from	the	ARTEMIS	DISK	Global	Antifungal	Surveillance	Study,	
1997	to	2007:	a	10.5-year	analysis	of	susceptibilities	of	Candida	Species	to	fluconazole	
and	voriconazole	as	determined	by	CLSI	standardized	disk	diffusion.	J.	Clin.	Microbiol.	
48,	1366–77.	
Pfaller,	M.A.,	Diekema,	D.J.,	Mendez,	M.,	Kibbler,	C.,	Erzsebet,	P.,	Chang,	S.-C.,	Gibbs,	D.L.,	
Newell,	V.A.,	2006.	Candida	guilliermondii,	an	opportunistic	fungal	pathogen	with	
decreased	susceptibility	to	fluconazole:	geographic	and	temporal	trends	from	the	
ARTEMIS	DISK	antifungal	surveillance	program.	J.	Clin.	Microbiol.	44,	3551–6.	
Pfeiffer,	C.D.,	Samsa,	G.P.,	Schell,	W.A.,	Reller,	L.B.,	Perfect,	J.R.,	Alexander,	B.D.,	2011.	
Quantitation	of	Candida	CFU	in	initial	positive	blood	cultures.	J.	Clin.	Microbiol.	49,	
2879–83.	
Pickering,	J.W.,	Sant,	H.W.,	Bowles,	C.A.P.,	Roberts,	W.L.,	Woods,	G.L.,	2005.	Evaluation	of	a	
(1->3)-beta-D-glucan	assay	for	diagnosis	of	invasive	fungal	infections.	J.	Clin.	Microbiol.	
43,	5957–62.	
Poulain,	D.,	Slomianny,	C.,	Jouault,	T.,	Gomez,	J.M.,	Trinel,	P.A.,	2002.	Contribution	of	
phospholipomannan	to	the	surface	expression	of	beta-1,2-oligomannosides	in	Candida	
albicans	and	its	presence	in	cell	wall	extracts.	Infect.	Immun.	70,	4323–8.	
Richet,	H.,	Roux,	P.,	Des	Champs,	C.,	Esnault,	Y.,	Andremont,	A.,	2002.	Candidemia	in	French	
hospitals:	incidence	rates	and	characteristics.	Clin.	Microbiol.	Infect.	8,	405–12.	
Ringdahl,	E.N.,	2000.	Treatment	of	recurrent	vulvovaginal	candidiasis.	Am.	Fam.	Physician	
61,	3306–12.	
37	
	
Safdar,	A.,	Armstrong,	D.,	2011.	Infections	in	patients	with	hematologic	neoplasms	and	
hematopoietic	stem	cell	transplantation:	neutropenia,	humoral,	and	splenic	defects.	
Clin.	Infect.	Dis.	53,	798–806.	
Sanguinetti,	M.,	Posteraro,	B.,	Fiori,	B.,	Ranno,	S.,	Torelli,	R.,	Fadda,	G.,	2005.	Mechanisms	of	
azole	resistance	in	clinical	isolates	of	Candida	glabrata	collected	during	a	hospital	
survey	of	antifungal	resistance.	Antimicrob.	Agents	Chemother.	49,	668–79.	
Santos,	M.A.,	Tuite,	M.F.,	1995.	The	CUG	codon	is	decoded	in	vivo	as	serine	and	not	leucine	
in	Candida	albicans.	Nucleic	Acids	Res.	23,	1481–6.	
Santos,	M.A.S.,	Gomes,	A.C.,	Santos,	M.C.,	Carreto,	L.C.,	Moura,	G.R.,	2011.	The	genetic	code	
of	the	fungal	CTG	clade.	C.	R.	Biol.	334,	607–11.	
Sarvikivi,	E.,	Lyytikäinen,	O.,	Soll,	D.R.,	Pujol,	C.,	Pfaller,	M.A.,	Richardson,	M.,	Koukila-
Kähkölä,	P.,	Luukkainen,	P.,	Saxén,	H.,	2005.	Emergence	of	fluconazole	resistance	in	a	
Candida	parapsilosis	strain	that	caused	infections	in	a	neonatal	intensive	care	unit.	J.	
Clin.	Microbiol.	43,	2729–35.	
Schell,	W.A.,	Benton,	J.L.,	Smith,	P.B.,	Poore,	M.,	Rouse,	J.L.,	Boles,	D.J.,	Johnson,	M.D.,	
Alexander,	B.D.,	Pamula,	V.K.,	Eckhardt,	A.E.,	Pollack,	M.G.,	Benjamin,	D.K.,	Perfect,	
J.R.,	Mitchell,	T.G.,	2012.	Evaluation	of	a	digital	microfluidic	real-time	PCR	platform	to	
detect	DNA	of	Candida	albicans	in	blood.	Eur.	J.	Clin.	Microbiol.	Infect.	Dis.	31,	2237–45.	
Sendid,	B.,	Poirot,	J.L.,	Tabouret,	M.,	Bonnin,	A.,	Caillot,	D.,	Camus,	D.,	Poulain,	D.,	2002.	
Combined	detection	of	mannanaemia	and	antimannan	antibodies	as	a	strategy	for	the	
diagnosis	of	systemic	infection	caused	by	pathogenic	Candida	species.	J.	Med.	
Microbiol.	51,	433–42.	
Sendid,	B.,	Tabouret,	M.,	Poirot,	J.L.,	Mathieu,	D.,	Fruit,	J.,	Poulain,	D.,	1999.	New	enzyme	
immunoassays	for	sensitive	detection	of	circulating	Candida	albicans	mannan	and	
antimannan	antibodies:	useful	combined	test	for	diagnosis	of	systemic	candidiasis.	J.	
Clin.	Microbiol.	37,	1510–7.	
Shahana,	S.,	Mora-Montes,	H.M.,	Castillo,	L.,	Bohovych,	I.,	Sheth,	C.C.,	Odds,	F.C.,	Gow,	
N.A.R.,	Brown,	A.J.P.,	2013.	Reporters	for	the	analysis	of	N-glycosylation	in	Candida	
albicans.	Fungal	Genet.	Biol.	56,	107–15.	
Singh-Babak,	S.D.,	Babak,	T.,	Diezmann,	S.,	Hill,	J.A.,	Xie,	J.L.,	Chen,	Y.-L.,	Poutanen,	S.M.,	
38	
	
Rennie,	R.P.,	Heitman,	J.,	Cowen,	L.E.,	2012.	Global	analysis	of	the	evolution	and	
mechanism	of	echinocandin	resistance	in	Candida	glabrata.	PLoS	Pathog.	8,	e1002718.	
Staniszewska,	M.,	Bondaryk,	M.,	Siennicka,	K.,	Kurzatkowski,	W.,	2012.	Ultrastructure	of	
Candida	albicans	pleomorphic	forms:	phase-contrast	microscopy,	scanning	and	
transmission	electron	microscopy.	Pol.	J.	Microbiol.	61,	129–35.	
Tavanti,	A.,	Davidson,	A.D.,	Gow,	N.A.R.,	Maiden,	M.C.J.,	Odds,	F.C.,	2005.	Candida	
orthopsilosis	and	Candida	metapsilosis	spp.	nov.	to	replace	Candida	parapsilosis	groups	
II	and	III.	J.	Clin.	Microbiol.	43,	284–92.	
Theel,	E.S.,	Doern,	C.D.,	2013.	β-D-glucan	testing	is	important	for	diagnosis	of	invasive	fungal	
infections.	J.	Clin.	Microbiol.	51,	3478–83.	
Thornton,	C.,	Johnson,	G.,	Agrawal,	S.,	2012.	Detection	of	invasive	pulmonary	aspergillosis	in	
haematological	malignancy	patients	by	using	lateral-flow	technology.	J.	Vis.	Exp.	
Thornton,	C.R.,	2001.	Molecular	and	Cellular	Biology	of	Filamentous	Fungi:	A	Practical	
Approach.	Oxford	University	Press.	
Thornton,	C.R.,	2008.	Development	of	an	immunochromatographic	lateral-flow	device	for	
rapid	serodiagnosis	of	invasive	aspergillosis.	Clin.	Vaccine	Immunol.	15,	1095–105.	
Thornton,	C.R.,	2009.	Tracking	the	emerging	human	pathogen	Pseudallescheria	boydii	by	
using	highly	specific	monoclonal	antibodies.	Clin.	Vaccine	Immunol.	16,	756–64.	
Torosantucci,	A.,	Gomez,	M.J.,	Bromuro,	C.,	Casalinuovo,	I.,	Cassone,	A.,	1991.	Biochemical	
and	antigenic	characterization	of	mannoprotein	constituents	released	from	yeast	and	
mycelial	forms	of	Candida	albicans.	Med.	Mycol.	29,	361–372.	
Trinel,	P.A.,	Borg-von-Zepelin,	M.,	Lepage,	G.,	Jouault,	T.,	Mackenzie,	D.,	Poulain,	D.,	1993.	
Isolation	and	preliminary	characterization	of	the	14-	to	18-kilodalton	Candida	albicans	
antigen	as	a	phospholipomannan	containing	beta-1,2-linked	oligomannosides.	Infect.	
Immun.	61,	4398–4405.	
Trinel,	P.-A.,	Plancke,	Y.,	Gerold,	P.,	Jouault,	T.,	Delplace,	F.,	Schwarz,	R.T.,	Strecker,	G.,	
Poulain,	D.,	1999.	The	Candida	albicans	Phospholipomannan	Is	a	Family	of	Glycolipids	
Presenting	Phosphoinositolmannosides	with	Long	Linear	Chains	of		-1,2-Linked	
Mannose	Residues.	J.	Biol.	Chem.	274,	30520–30526.	
39	
	
Verduyn	Lunel,	F.M.,	Donnelly,	J.P.,	van	der	Lee,	H.A.L.,	Blijlevens,	N.M.A.,	Verweij,	P.E.,	
2009.	Circulating	Candida-specific	anti-mannan	antibodies	precede	invasive	candidiasis	
in	patients	undergoing	myelo-ablative	chemotherapy.	Clin.	Microbiol.	Infect.	15,	380–6.	
Vincent,	J.L.,	Anaissie,	E.,	Bruining,	H.,	Demajo,	W.,	El-Ebiary,	M.,	Haber,	J.,	Hiramatsu,	Y.,	
Nitenberg,	G.,	Nyström,	P.O.,	Pittet,	D.,	Rogers,	T.,	Sandven,	P.,	Sganga,	G.,	Schaller,	
M.D.,	Solomkin,	J.,	2014.	Epidemiology,	diagnosis	and	treatment	of	systemic	Candida	
infection	in	surgical	patients	under	intensive	care.	Intensive	Care	Med.	24,	206–216.	
White,	P.L.,	Parr,	C.,	Thornton,	C.,	Barnes,	R.A.,	2013.	Evaluation	of	real-time	PCR,	
galactomannan	enzyme-linked	immunosorbent	assay	(ELISA),	and	a	novel	lateral-flow	
device	for	diagnosis	of	invasive	aspergillosis.	J.	Clin.	Microbiol.	51,	1510–6.	
Wingard,	J.R.,	1995.	Importance	of	Candida	species	other	than	C.	albicans	as	pathogens	in	
oncology	patients.	Clin.	Infect.	Dis.	20,	115–25.	
Wisplinghoff,	H.,	Bischoff,	T.,	Tallent,	S.M.,	Seifert,	H.,	Wenzel,	R.P.,	Edmond,	M.B.,	2004.	
Nosocomial	bloodstream	infections	in	US	hospitals:	analysis	of	24,179	cases	from	a	
prospective	nationwide	surveillance	study.	Clin.	Infect.	Dis.	39,	309–17.	
Yang,	Y.-L.,	Chu,	W.-L.,	Lin,	C.-C.,	Tsai,	S.-H.,	Chang,	T.-P.,	Lo,	H.-J.,	2014.	An	emerging	issue	
of	mixed	yeast	cultures.	J.	Microbiol.	Immunol.	Infect.	47,	339–44.	
Yera,	H.,	Sendid,	B.,	Francois,	N.,	Camus,	D.,	Poulain,	D.,	2001.	Contribution	of	serological	
tests	and	blood	culture	to	the	early	diagnosis	of	systemic	candidiasis.	Eur.	J.	Clin.	
Microbiol.	Infect.	Dis.	20,	864–70.	
Ylipalosaari,	P.,	Ala-Kokko,	T.I.,	Karhu,	J.,	Koskela,	M.,	Laurila,	J.,	Ohtonen,	P.,	Syrjälä,	H.,	
2012.	Comparison	of	the	epidemiology,	risk	factors,	outcome	and	degree	of	organ	
failures	of	patients	with	candidemia	acquired	before	or	during	ICU	treatment.	Crit.	care	
16,	62.	
	
